FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 353:2550-2558 December 15, 2005 Number 24 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Supplementary Material Editorial by Bermas, B. L. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background Oral contraceptives are rarely prescribed for women with systemic lupus erythematosus, because of concern about potential negative side effects. In this double-blind, randomized, noninferiority trial, we prospectively evaluated the effect of oral contraceptives on lupus activity in premenopausal women with systemic lupus erythematosus.

Methods A total of 183 women with inactive (76 percent) or stable active (24 percent) systemic lupus erythematosus at 15 U.S. sites were randomly assigned to receive either oral contraceptives (triphasic ethinyl estradiol at a dose of 35 µg plus norethindrone at a dose of 0.5 to 1 mg for 12 cycles of 28 days each; 91 women) or placebo (92 women) and were evaluated at months 1, 2, 3, 6, 9, and 12. Subjects were excluded if they had moderate or high levels of anticardiolipin antibodies, lupus anticoagulant, or a history of thrombosis.

Results The primary end point, a severe lupus flare, occurred in 7 of 91 subjects receiving oral contraceptives (7.7 percent) as compared with 7 of 92 subjects receiving placebo (7.6 percent). The 12-month rates of severe flare were similar: 0.084 for the group receiving oral contraceptives and 0.087 for the placebo group (P=0.95; upper limit of the one-sided 95 percent confidence interval for this difference, 0.069, which is within the prespecified 9 percent margin for noninferiority). Rates of mild or moderate flares were 1.40 flares per person-year for subjects receiving oral contraceptives and 1.44 flares per person-year for subjects receiving placebo (relative risk, 0.98; P=0.86). In the group that was randomized to receive oral contraceptives, there was one deep venous thrombosis and one clotted graft; in the placebo group, there was one deep venous thrombosis, one ocular thrombosis, one superficial thrombophlebitis, and one death (after cessation of the trial).

Conclusions Our study indicates that oral contraceptives do not increase the risk of flare among women with systemic lupus erythematosus whose disease is stable.

Source Information

From Johns Hopkins University School of Medicine, Baltimore (M.P., L.S., M.F.); Albert Einstein College of Medicine–Montefiore Medical Center, Bronx, N.Y. (M.Y.K., B.D., M.M.); University of California, Los Angeles (K.C.K., J.G., B.H.H.); Hospital for Special Surgery, New York (L.R.S., M.L.); Oklahoma Medical Research Foundation, Oklahoma City (J.T.M.); the Hospital for Joint Diseases and Bellevue Hospital at New York University School of Medicine, New York (H.M.B., A.D.A., A.R., F.L., J.P.B.); University of Michigan, Ann Arbor (W.J.M.); Louisiana State University Health Sciences Center, Shreveport (M.H.-H.); University of North Carolina at Chapel Hill, Chapel Hill (M.A.D.); University of Pennsylvania, Philadelphia (J.V.F.); University of Texas, Houston (A.F.); Rheumatology Associates of Long Island, Port Jefferson Station, N.Y. (M.T.); University of California, San Francisco, San Francisco (J.D.); and Medical College of Wisconsin, Milwaukee (M.C.).

Address reprint requests to Dr. Buyon at the Department of Rheumatology, Rm. 1608, Hospital for Joint Diseases, 301 E. 17th St., New York, NY 10003, or at jill.buyon{at}nyumc.org.

Full Text of this Article

Related Letters:

Oral Contraceptives in Women with Systemic Lupus Erythematosus
Schwarz E. B., Lohr P. A., Sánchez-Guerrero J., Jiménez-Santana L., Cravioto M.-d.-C.
Extract | Full Text | PDF  
N Engl J Med 2006; 354:1203-1204, Mar 16, 2006. Correspondence

This article has been cited by other articles:

• Petri, M, Singh, S, Tesfasyone, H, Dedrick, R, Fry, K, Lal, P., Williams, G, Bauer, J., Gregersen, P., Behrens, T., Baechler, E. (2009). Longitudinal expression of type I interferon responsive genes in systemic lupus erythematosus. Lupus 18: 980-989 [Abstract]  
• KIANI, A. N., JOHNSON, K., CHEN, C., DIEHL, E., HU, H., VASUDEVAN, G., SINGH, S., MAGDER, L. S., KNECHTLE, S. J., PETRI, M. (2009). Urine Osteoprotegerin and Monocyte Chemoattractant Protein-1 in Lupus Nephritis. The Journal of Rheumatology 36: 2224-2230 [Abstract] [Full Text]  
• BINGHAM, C. O. III, POHL, C., WOODWORTH, T. G., HEWLETT, S. E., MAY, J. E., RAHMAN, M. U., WITTER, J. P., FURST, D. E., STRAND, C. V., BOERS, M., ALTEN, R. E. (2009). Developing a Standardized Definition for Disease "Flare" in Rheumatoid Arthritis (OMERACT 9 Special Interest Group). The Journal of Rheumatology 36: 2335-2341 [Abstract] [Full Text]  
• APPENZELLER, S., CLARKE, A. E., PANOPALIS, P., JOSEPH, L., ST. PIERRE, Y., LI, T. (2009). The Relationship Between Renal Activity and Quality of Life in Systemic Lupus Erythematosus. The Journal of Rheumatology 36: 947-952 [Abstract] [Full Text]  
• Gordon, C, Bertsias, G, Ioannidis, J P A, Boletis, J, Bombardieri, S, Cervera, R, Dostal, C, Font, J, Gilboe, I-M, Houssiau, F, Huizinga, T W J, Isenberg, D, Kallenberg, C G M, Khamashta, M A, Piette, J-C, Schneider, M, Smolen, J S, Sturfelt, G, Tincani, A, Van Vollenhoven, R, Boumpas, D T (2009). EULAR points to consider for conducting clinical trials in systemic lupus erythematosus. Ann Rheum Dis 68: 470-476 [Abstract] [Full Text]  
• MANZI, S. (2009). Lupus update: Perspective and clinical pearls. Cleveland Clinic Journal of Medicine 76: 137-142 [Abstract] [Full Text]  
• ASKANASE, A. D., WALLACE, D. J., WEISMAN, M. H., TSENG, C.-E, BERNSTEIN, L., BELMONT, H. M., SEIDMAN, E., ISHIMORI, M., IZMIRLY, P. M., BUYON, J. P. (2009). Use of Pharmacogenetics, Enzymatic Phenotyping, and Metabolite Monitoring to Guide Treatment with Azathioprine in Patients with Systemic Lupus Erythematosus. The Journal of Rheumatology 36: 89-95 [Abstract] [Full Text]  
• Dhanjal, M. K (2008). Contraception in women with medical problems. Obstet Med 1: 78-87 [Abstract] [Full Text]  
• Yuen, S. Y., Pope, J. E. (2008). Learning from past mistakes: assessing trial quality, power and eligibility in non-renal systemic lupus erythematosus randomized controlled trials. Rheumatology (Oxford) 47: 1367-1372 [Abstract] [Full Text]  
• Petri, M, Buyon, J. (2008). Editorial: Oral contraceptives in systemic lupus erythematosus: the case for (and against). Lupus 17: 708-710  
• Cohen-Solal, J., Jeganathan, V, Hill, L, Kawabata, D, Pinto-Rodriguez, D, Grimaldi, C, Diamond, B (2008). Hormonal regulation of B-cell function and systemic lupus erythematosus. Lupus 17: 528-532 [Abstract]  
• Petri, M (2008). Sex hormones and systemic lupus erythematosus. Lupus 17: 412-415 [Abstract]  
• Legro, R. S., Pauli, J. G., Kunselman, A. R., Meadows, J. W., Kesner, J. S., Zaino, R. J., Demers, L. M., Gnatuk, C. L., Dodson, W. C. (2008). Effects of Continuous Versus Cyclical Oral Contraception: A Randomized Controlled Trial. J. Clin. Endocrinol. Metab. 93: 420-429 [Abstract] [Full Text]  
• Bertsias, G, Ioannidis, J P A, Boletis, J, Bombardieri, S, Cervera, R, Dostal, C, Font, J, Gilboe, I M, Houssiau, F, Huizinga, T, Isenberg, D, Kallenberg, C G M, Khamashta, M, Piette, J C, Schneider, M, Smolen, J, Sturfelt, G, Tincani, A, van Vollenhoven, R, Gordon, C, Boumpas, D T (2008). EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis 67: 195-205 [Abstract] [Full Text]  
• Petri, M. (2007). Disease activity assessment in SLE: do we have the right instruments?. Ann Rheum Dis 66: iii61-iii64 [Abstract] [Full Text]  
• Wang, F., Roberts, S. M., Butfiloski, E. J., Morel, L., Sobel, E. S. (2007). Acceleration of Autoimmunity by Organochlorine Pesticides: A Comparison of Splenic B-Cell Effects of Chlordecone and Estradiol in (NZBxNZW)F1 Mice. Toxicol Sci 99: 141-152 [Abstract] [Full Text]  
• Tincani, A., Nuzzo, M., Lojacono, A., Cattalini, M., Meini, A. (2007). Review: Contraception in adolescents with systemic lupus erythematosus. Lupus 16: 600-605 [Abstract]  
• Straub, R. H. (2007). The Complex Role of Estrogens in Inflammation. Endocr. Rev. 28: 521-574 [Abstract] [Full Text]  
• Hellmann, D. B., Imboden, J. B. (2006). Update in Rheumatology. ANN INTERN MED 145: 834-838 [Full Text]  
• Li, X, Rider, V, Kimler, B F, Abdou, N I (2006). Estrogen does not regulate CD154 mRNA stability in systemic lupus erythematosus T cells. Lupus 15: 852-857 [Abstract]  
• Lockshin, M D (2006). Sex differences in autoimmune disease. Lupus 15: 753-756 [Abstract]  
• Vasoo, S (2006). Drug-induced lupus: an update. Lupus 15: 757-761 [Abstract]  
• (2006). Additional articles abstracted in ACP Journal Club. Evid. Based Med. 11: 94-94 [Full Text]  
• D'Cruz, D. P (2006). Systemic lupus erythematosus.. BMJ 332: 890-894 [Full Text]  
• Schwarz, E. B., Lohr, P. A., Sanchez-Guerrero, J., Jimenez-Santana, L., Cravioto, M.-d.-C. (2006). Oral contraceptives in women with systemic lupus erythematosus.. NEJM 354: 1203-1204 [Full Text]  
• (2006). Which Contraceptives for Women with Lupus?. JWatch Women's Health 2006: 4-4 [Full Text]  
• Bermas, B. L. (2005). Oral Contraceptives in Systemic Lupus Erythematosus -- A Tough Pill to Swallow?. NEJM 353: 2602-2604 [Full Text]